Reversal of chronic obstructive pulmonary disease-associated weight loss: Are there pharmacological treatment options?

Drugs

Volumn 64, Issue 10, 2004, Pages 1041-1052

  Berry, Jean K ^a   Baum, Charles ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b Alexion Brothers Hospital Network   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; DECANOIC ACID; HORMONE; HUMAN GROWTH HORMONE; LEUKOTRIENE; METHYLTESTOSTERONE; NANDROLONE; OXANDROLONE; PREDNISONE; STANOZOLOL; TUMOR NECROSIS FACTOR ALPHA;

ALOPECIA; BODY MASS; BREAST CARCINOMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE SEVERITY; DUAL ENERGY X RAY ABSORPTIOMETRY; EDEMA; EXERCISE; HUMAN; MEDICAL RESEARCH; NAUSEA; NONHUMAN; NUTRITIONAL STATUS; PROSTATE CANCER; REVIEW; SIDE EFFECT; UNDERWEIGHT; WEIGHT REDUCTION;

ADRENAL CORTEX HORMONES; ANABOLIC AGENTS; ANOXIA; ANTI-INFLAMMATORY AGENTS; CYTOKINES; ENERGY METABOLISM; HUMAN GROWTH HORMONE; HUMANS; MODELS, BIOLOGICAL; NUTRITION THERAPY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS; WEIGHT LOSS;

EID: 2942571459     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464100-00002     Document Type: Review

References (64)

1. Congleton J. The pulmonary cachexia syndrome: aspects of energy balance. Proc Nutr Soc 1999; 58: 321-8
2. Wilson DO, Rogers RM, Wright EC, et al. Body weight in chronic obstructive pulmonary disease: the National Institutes of Health Intermittent Positive Pressure Breathing Trial. Am Rev Respir Dis 1989; 139: 1435-8
3. Schols AM, Mostert R, Soeters P. et al. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis 1993; 147: 1151-6
4. Thorsdottir I, Gunnarsdottir I, Eriksen B, et al. Screening method evaluated by nutritional status measurements can be used to detect malnourishment in chronic obstructive pulmonary disease. J Am Diet Assoc 2001; 101: 648-54
5. Landbo C, Prescott E, Lange P, et al. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 1856-61
6. Foley R, Zu Wallack R. The impact of nutritional depletion in chronic obstructive pulmonary disease. J Cardiopulm Rehabil 2001; 21: 188-95
7. Pauwels A, Buist S, Calverley PMA, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 1256-76
8. Sahebjami H, Sathianpitayakus E. Influence of body weight on the severity of dyspnea in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 886-90
9. Wouters E. Nutrition and metabolism in COPD. Chest 2000; 117 (5 Suppl. 1): 274S-80
10. Arora NS, Rochester DF. Effect of body weight and muscularity of human diaphragm muscle mass, thickness, and area. Am Rev Respir Dis 1982; 126: 64-70
11. Engelen MP, Schols AM, Baken WC, et al. Nutritional depletion in relation to respiratory and peripheral skeletal muscle function in out patients with COPD. Eur Respir J 1994; 7: 1793-7
12. Lewis N, Monn SA, Zhan A, et al. Interactive effects of emphysema and malnutrition on diaphragm structure and function. J Appl Physiol 1994; 77: 947-55
13. Grey-Donald DK, Gibbons L, Shapiro S. Nutritional status and mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 153: 961-6
14. Palange P, Forte S, Onorati P, et al. Effect of reduced body weight on muscle aerobic capacity in patients with COPD. Chest 1998; 114: 12-8
15. Gosker H, Englene M, Mameren H, et al. Muscle fiber type IIX atrophy is involved in the loss of fat-free mass in chronic obstructive pulmonary disease. Am J Clin Nutr 2002; 76: 113-9
16. Fiaccadori E, Del Canale S, Coffrini E, et al. Hypercapnic-hypoxemic chronic obstructive pulmonary disease (COPD): influence of severity of COPD on nutritional status. Am J Clin Nutr 1998; 48: 680-5
17. Pouw EM, Ten Velde GP, Croonen BH, et al. Early non-elective readmission for chronic obstructive pulmonary disease is associated with weight loss. Clin Nutr 2000; 19: 95-9
18. Gross N. Extrapulmonary effects of chronic obstructive pulmonary disease. Curr Opin Pulm Med 2001; 7: 84-92
19. Iqbal F, Michaelson J, Thaler L, et al. Declining bone mass in men with chronic pulmonary disease: contribution of glucocorticoid treatment, body mass index, and gonadal function. Chest 1999; 116: 1616-24
20. Fletcher EC, Martin R. Sexual dysfunction and erectile impotence in chronic obstructive pulmonary disease. Chest 1982; 81: 413-21
21. MacAdams MR, White RH, Chipps BE. Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Intern Med 1986; 104: 648-51
22. Morrison D, Capewell S, Reynolds SP, et al. Testosterone levels during systemic and inhaled corticosteroid therapy. Respir Med 1994 Oct; 88 (9): 659-63
23. Storer TW, Magliano L, Woodhouse L, et al. Testosterone dose-dependently increases maximal voluntary strength and leg power, but does not affect fatigability or specific tension. J Clin Endocrinol Metab 2003; 88: 1478-85
24. Sih R, Morley JE, Kaiser FE, et al. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 1997; 82: 1661-7
25. Creutzberg EC, Schols AM, Bothermer-Quaedvlieg FC, et al. Prevalence of an elevated resting energy expenditure in patients with chronic obstructive pulmonary disease in relation to body composition and lung function. Eur J Clin Nutr 1998; 52: 1-6
26. Mannix ET, Manfredi F, Farber MO. Elevated O2 cost of ventilation contributes to tissue wasting in COPD. Chest 1999; 115: 708-13
27. Baarends EM, Schols AM, Westerterp KR, et al. Total daily energy expenditure relative to resting energy expenditure in clinically stable patients with COPD. Thorax 1997; 52: 780-5
28. Sridhar JK, Carter R, Lean MEJ, et al. Resting energy expenditure and nutritional state of patients with increased oxygen cost of breathing due to emphysema, scoliosis and thoracoplasty. Thorax 1994; 49: 781-5
29. Mitch WE, Goldberg AL. Mechanisms of disease: mechanisms of muscle wasting: the role of the ubiquitin-proteasome pathway. N Engl J Med 1996; 335: 1897-905
30. Schols AM, Buurman WA, Dentener MA, et al. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax 1996; 51: 819-24
31. Pitsiou G, Kyriazis G, Hatrzizisi O, et al. Tumor necrosis factor-alpha serum levels, weight loss and tissue oxygenation in chronic obstructive pulmonary disease. Respir Med 2002; 96 (8): 594-8
32. Takabatake N, Nakamura H, Abe S, et al. The relationship between chronic hypoxemia and activation of the tumor necrosis factor-α system in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 1179-84
33. Fandrey J. Hypoxia-inducible gene expression. Respir Physiol 1995; 101: 1-10
34. Hempel SL, Monick MM, He B, et al. Synthesis of prostaglandin H synthase-2 by human alveolar macrophages in response to lipopolysaccharide is inhibited by decreased cell oxidant tone. J Biol Chem 1994; 269: 32979-84
35. Hempel SL, Monick MM, Hunninghake GW. Effect of hypoxia on release of IL-1 and TNF by human alveolar macrophages. Am J Respir Cell Mol Biol 1996; 14: 170-6
36. Madjdpour D, Jewell UR, Kneller S, et al. Decreased alveolar oxygen induces lung inflammation. Am J Physiol Lung Cell Mol Physiol 2003; 284: L360-7
37. Leeper-Woodford SK, Detmer K. Acute hypoxia increases alveolar macrophage tumor necrosis factor activity and alters NF-κB expression. Am J Physiol 1999; 276: L909-16
38. Koong AC, Chen EY, Giaccia AJ. Hypoxia causes the activation of nuclear factor κB through the phosphorylation and IκBα on tyrosine residues. Cancer Res 1994; 54: 1425-30
39. Taylor CT, Fueki N, Agah A, et al. Critical role of cAMP response element binding protein expression in hypoxia-elicited induction of epithelial tumor necrosis factor-α. J Biol Chem 1999; 274: 19447-54
40. de Godoy I, Donahoe M, Calhoun WJ, et al. Elevated TNF-alpha production by peripheral blood monocytes of weight-losing COPD patients. Am J Respir Crit Care Med 1996; 153: 633-7
41. Ioko Y, Tatsusmi K, Sugito K, et al. Effects of insulin-like growth factor on weight gain in chronic hypoxic rats. J Cardiovasc Pharmacol 2002; 39: 636-42
42. Decramer M, Lacquet LM, Fagard R, et al. Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med 1994; 150: 11-6
43. Wing SS, Goldberg AL. Glucocorticoids activate the ATP-ubiquitin- proteolytic system in skeletal muscle during fasting. Am J Physiol 1993; 264: E668-76
44. Jenkins RC, Ross RJ. Growth hormone therapy for protein catabolism. QJM 1996; 89: 813-9
45. Jurasinski CV, Kilpatrick L, Vary TC. Amrinone prevents muscle protein wasting during chronic sepsis. Am J Physiol 1995; 268: E491-500
46. Frost RA, Lang CH, Gelato MC. Transient exposure of human myoblasts to tumor necrosis factor-alpha inhibits serum and insulin-like growth factor-I stimulated protein synthesis. Endocrinology 1997; 138: 4153-9
47. Ward HC, Halliday D, Sim AJW. Protein and energy metabolism with biosynthetic human growth hormone after gastrointestinal surgery. Ann Surg 1987; 206: 56-61
48. Mulligan KC, Grunfeld MK, Hellerstein RA, et al. Anabolic effects of recombinant human growth hormone in patients requiring prolonged mechanical ventilation. J Clin Endocrinol Metab 1993; 77: 956-62
49. Horber FF, Haymond MW. Human growth hormone prevents the protein catabolic side effect of prednisone in humans. J Clin Invest 1990; 86: 265-72
50. Suchner U, Rothkopf MM, Stanislaus G, et al. The effect of growth hormone on weight gain and pulmonary function in patients with chronic obstructive lung disease. Arch Intern Med 1990; 150: 1225-39
51. Pape GS, Friedman M, Underwood LE, et al. The effect of growth hormone on weight gain and pulmonary function in patients with chronic obstructive lung disease. Chest 1991; 99: 1495-500
52. Burdet L, Muralt BD, Schutz Y, et al. Administration of growth hormone to underweight patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997; 156: 1800-6
53. Schols AM, Soeteres PB, Mostert R, et al. Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease: a placebo-controlled randomized trial. Am J Respir Crit Care Med 1995; 152: 1268-74
54. Ferreira IM, Verreschi IT, Nery LE, et al. The influence of 6 months of oral anabolic steroids on body mass and respiratory muscles in undernourished COPD patients. Chest 1998; 114: 19-28
55. Yeh SS, DeGuzman B, Kramer T. Reversal of COPD-associated weight loss using the anabolic agent drolone. Chest 2002; 122: 421-8
56. Weisberg J, Wanter J, Ollson J, et al. strol acetate stimulates weight gain and ventilation in underweight COPD patients. Chest 2002; 121: 1070-8
57. Jardin JR, Ferreira IM, Sacks A. Nutrition, anabolic steroids and growth hormone in pulmonary rehabilitation. Phys Med Rehab Clin North Am 1996; 7: 253-75
58. De Boer WI. Cytokines and therapy in COPD: a promising combination? Chest 2002; 121: 209s-18
59. Barnes PJ. Potential novel therapies for chronic obstructive pulmonary disease. Novartis Found Symp 2001; 234: 255-67
60. Marchesani F, Valeriao G, Dardes N, et al. Effect of intravenous fructose 1,6 diphosphate administration in malnourished chronic obstructive pulmonary disease patients with chronic respiratory failure. Respiration 2000; 67: 177-82
61. Creutzberg EC, Wouters EFM, Mostert R, et al. Efficacy of nutritional supplementation therapy in depleted patients with chronic obstructive pulmonary disease. Nutrition 2003; 19: 120-7
62. Schwartz J. Role of polyunsaturated fatty acids in lung disease. Am J Clin Nutr 2000; 71 (1 Suppl.): 393S-6S
63. Pacht ER, De Michele SJ, Nelson JL, et al. Enterai nutrition with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants reduces alveolar inflammatory mediators and protein influx in patients with acute respiratory distress syndrome. Crit Care Med 2003; 31: 491-500
64. Diez JJ, Inglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 2003; 148: 293-300